Abstract
Agomelatine is an antidepressant drug acting as melatonergic MT1- and MT2-receptor agonist and selective serotonergic 5-HT2C-antagonist. The efficacy in treatment of major depressive disorder was established in randomized, double-blind, placebo controlled studies and a maintenance study in adult in- and outpatients. Positive effects on sleep parameters have been reported. Side effects are rare; weight gain, sexual dysfunction, or discontinuation syndromes are missing; increase of hepatic transaminases values must be monitored, however; and agomelatine is contraindicated in patients with liver impairment.
Similar content being viewed by others
References
Cipriani A, Furukawa TA, Salanti G, Chaimani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–66.
Corruble E, de Bodinat C, Belaidi C, Goodwin G. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16:2219–34.
De Berardis D, Conti CM, Marini S, Ferri F, et al. Is there a role for agomelatine in the treatment of anxiety disorders? A review of published data. Int J Immunopath Pharmacol. 2013;26:299–304.
Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kapser S. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr. 2013;18:163–70.
Dridi D, Zouiten A, Mansour HB. Depression: chronophysiology and chronotherapy. Biol Rhythm Res. 2013;45:77–91.
Friedrich ME, Akimova E, Huf W, Konstantinidis A, et al. Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol. 2016;19:pyv126.
Goodwin G, Emsley R, Rembry S, Rouillon F, et al. Agomelatine prevents relapse in patients with major depressive disorder, without evidence of a discontinuation syndrome. J Clin Psychiatry. 2009;70:1128–37.
Gorwood P, Benichou J, Moore N, Martínez EA, et al. The safety of agomelatine in standard medical practice in depressed patients: a 26-week international multicentre cohort study. Hum Psychopharmacol. 2021;36:e2759.
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;12:CD008851.
Hale A, Corral R, Mencacci O, Saiz Ruiz J, Albarran SC. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomised, double-blind study. Int Clin Psychopharmacol. 2010;25:305–14.
Heun R, Ahokas A, Boyer P, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder. A placebo-controlled study. J Clin Psychiatry. 2013;74:587–94.
Hiemke C, Bergemann N, Clement HW, Conca A, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709–31.
Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry. 2009;10:117–26.
Kasper S, Hajak G, Wulff K, Hoogendijk WJ, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109–20.
Kasper S, Corruble E, Hale A, Lemoine P, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol. 2013;28:12–9.
Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder. CNS Drugs. 2010;24:479–99.
Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry. 2013;203:179–87.
Laux G. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry. 2012;45:284–29.
Laux G, Barthel B, Hajak G, et al. Pooled analysis of four non-interventional studies: Effectiveness and tolerability of the antidepressant agomelatine in daily practice. Adv Ther. 2017;34:895–914.
Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68:1723–32.
Martinotti G, Sepede G, Gambi F, Di Iorio G, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012;32:487–91.
Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954–64.
Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol. 2007;22:283–91.
Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19:271–80.
Norman TR, Olver JS. Agomelatine for depression: expanding the horizons? Expert Opin Pharmacother. 2019;20:647–56.
Nussbaumer-Streit B, Greenblatt A, Kaminski-Hartenthaler A, et al. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2019;6:CD011271.
Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10:661–73.
Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. J Psychiatr Res. 2018;101:72–9.
Pjrek E, Winkler D, Konstantinidis A, Willeit M, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl). 2007;190:575–9.
Pladevall-Vila M, Pottegård A, Schink T, Reutfors J, et al. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case–control study using automated health data sources. CNS Drugs. 2019;33:383–95.
Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10:691–6.
Quera-Salva MA, Hajak G, Philip P, Montplaisir J, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011;26:252–62.
Racagni G, Riva MA, Molteni R, Musazzi L, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry. 2011;12:574–87.
Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2012;15:417–28.
Stein DJ, Ahokas A, Marquez MS, Höschl C, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry. 2014;75:362–8.
Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Laux, G. (2021). Agomelatine and Depressions. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_31-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_31-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine